Abstracts

TREATMENT OUTCOMES OF PERSONS WITH DSTB ON A MEDICATION MONITOR AND ADHERENCE SUPPORT

Background: Digital adherence technologies have gained traction recently with medication monitors showing improved adherence. Data on the impact on long-term clinical outcomes is lacking. We conducted a cluster-randomized trial to measure outcomes amongst persons with drug-susceptible TB (DS-TB) supported by medication monitors and differentiated care (intervention) versus standard care (SoC). Participants had improved adherence in…

WEIGHT GAIN AMONG PARTICIPANTS SWITCHING TO A DOLUTEGRAVIR-BASED HIV REGIMEN IN KENYA

Background: Dolutegravir (DTG) use has been associated with increased risk for weight gain. We have previously demonstrated that ART-naïve patients starting DTG in Kenya gain significantly more weight compared to those starting a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). In this study we determined the impact of switching from NNRTI, efavirenz (EFV) or nevirapine (NVP), to…

REVERSIBILITY OF TAF- AND/OR InSTI-ASSOCIATED WEIGHT GAIN

Background: We and others have previously reported that excessive weight gain (WG) is common in virally suppressed people with HIV (PWH) after switching to TAF and/or INSTI. Data on reversibility of TAF and/or INSTI-associated WG are currently limited to case reports. Methods: From the Dutch ATHENA Cohort, we selected all PWH with ≥7% WG within…

FAVORABLE METABOLIC OUTCOMES 48 WEEKS AFTER SWITCH TO DTG/3TC

Background: Since 1996, triple drug antiretroviral therapy (ART) is standard in HIV care. Nowadays, with the increased viral potency of new antiretroviral drugs, dual ART has become a valid and potentially less toxic alternative considering the (present) lifelong need of ART. Metabolic complications such as weight gain have been reported with newer agents such as…

WEIGHT LOSS AND METABOLIC CHANGES AFTER SWITCHING FROM TAF/FTC/DTG TO TDF/3TC/DTG

Background: Use of tenofovir alafenamide (TAF) with emtricitabine (FTC) and integrase inhibitors such as dolutegravir (DTG) has been associated with significant treatment-emergent weight gain and higher risks of metabolic syndrome. Weight gain is particularly high for Black women on first-line antiretrovirals. Efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) could suppress weight gain. It is unclear…